NERV - Minerva Neurosciences, Inc.
| Previous Close | 4.4000 |
| Open | 4.4200 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 800 |
| Day's Range | 4.3600 - 4.5500 |
| 52 Week Range | 4.3600 - 12.9500 |
| Volume | 205,388 |
| Avg. Volume | 149,579 |
| Market Cap | 170.932M |
| Beta (3Y Monthly) | 1.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3790 |
| Earnings Date | Nov 1, 2017 - Nov 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.75 |
- GlobeNewswire•6 days ago
Minerva Neurosciences to Present at JMP Securities Life Sciences Conference
WALTHAM, Mass., June 12, 2019 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to.
- GlobeNewswire•20 days ago
Minerva Neurosciences to Present at Jefferies 2019 Global Healthcare Conference on June 4, 2019
WALTHAM, Mass., May 29, 2019 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to.
- Benzinga•last month
Minerva Neurosciences Sinks To Lowest Level In A Year On Cloudy Midstage Trial Results For Depression Drug
The drug was evaluated in adult patients with major depressive disorder who have responded inadequately to selective serotonin reuptake inhibitors and/or serotonin-norepinephrine reuptake inhibitors.
- GlobeNewswire•last month
Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced positive results from a Phase 2b clinical trial of seltorexant (MIN-202) as adjunctive therapy to antidepressants in adult patients with major depressive disorder (MDD) who have responded inadequately to selective serotonin reuptake inhibitors (SSRIs) and/or serotonin-norepinephrine reuptake inhibitors (SNRIs). In this dose finding study, the 20 milligram (mg) dose of seltorexant, under co-development with Janssen Pharmaceutica NV, showed a statistically significant improvement in the MADRS (Montgomery-Asberg Depression Rating Scale) score compared to placebo.
- Thomson Reuters StreetEvents•last month
Edited Transcript of NERV earnings conference call or presentation 6-May-19 12:30pm GMT
Q1 2019 Minerva Neurosciences Inc Earnings Call
- Simply Wall St.•last month
Calculating The Fair Value Of Minerva Neurosciences, Inc. (NASDAQ:NERV)
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Does the May share price for Minerva Neurosciences, Inc. (NASDAQ:NERV) reflect what it's really worth...
Motley Fool•last monthMinerva Neurosciences, Inc. (NERV) Q1 2019 Earnings Call Transcript
NERV earnings call for the period ending March 31, 2019.
- Associated Press•last month
Minerva Neurosciences: 1Q Earnings Snapshot
The Waltham, Massachusetts-based company said it had a loss of 41 cents per share. Minerva Neurosciences shares have increased 12% since the beginning of the year. The stock has risen 22% in the last 12 ...
- GlobeNewswire•last month
Minerva Neurosciences Reports First Quarter 2019 Financial Results and Business Updates
WALTHAM, Mass., May 06, 2019 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central.
- GlobeNewswire•2 months ago
Minerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6, 2019
WALTHAM, Mass., April 29, 2019 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat.
- GlobeNewswire•2 months ago
Minerva Neurosciences Presents Pre-Clinical Data Suggesting a Mechanistic Role of Roluperidone in Addressing Negative Symptoms of Schizophrenia
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the presentation of a poster at the 2019 Congress of the Schizophrenia International Research Society in Orlando, Florida entitled Roluperidone increases in-vitro Brain-Derived Neurotrophic Factor (BDNF) release: a possible mechanistic role in negative symptoms? Findings to be presented in Poster #T145 during Poster Session 1 on April 11, 2019, 12:00 p.m. – 2:00 p.m., demonstrate that administration of roluperidone significantly increased BDNF release by astrocytes and hippocampal neurons obtained from the cerebral cortex of newborn rats, as well as the release of GDNF (Glial cell derived neurotrophic factor) in cultured astrocytes. Furthermore, data showed that roluperidone enhanced BDNF gene expression at drug concentrations similar to those observed in humans at tested doses.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of NERV earnings conference call or presentation 12-Mar-19 12:30pm GMT
Q4 2018 Minerva Neurosciences Inc Earnings Call
- GlobeNewswire•3 months ago
Minerva Neurosciences to Host Webcast Event on Schizophrenia
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a webcast, “Schizophrenia: Disease Landscape and Forecast,” on Thursday, March 21, 2019 beginning at 10:00 a.m. eastern time in Boston, MA. Minerva’s Executive Chairman and Chief Executive Officer, Remy Luthringer, Ph.D., will be joined by representatives from Decision Resources Group, a global information and technology services company providing proprietary data and solutions to the healthcare industry, and Dr. Gregory Strauss, an expert key opinion leader.
Motley Fool•3 months agoMinerva Neurosciences Inc (NERV) Q4 2018 Earnings Conference Call Transcript
NERV earnings call for the period ending December 31, 2018.
- Associated Press•3 months ago
Minerva Neurosciences: 4Q Earnings Snapshot
The Waltham, Massachusetts-based company said it had a loss of 34 cents per share. For the year, the company reported that its loss widened to $50.2 million, or $1.29 per share. Minerva Neurosciences shares ...
- GlobeNewswire•3 months ago
Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates
Recruitment active in five late-stage trials with three compounds directed toward significant unmet medical needs Target indications include schizophrenia, major depressive.
- GlobeNewswire•3 months ago
Minerva Neurosciences to Report Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2019
WALTHAM, Mass., March 05, 2019 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat.
- GlobeNewswire•4 months ago
Factors of Influence in 2019, Key Indicators and Opportunity within Wright Medical Group N.V, MSA Safety Incorporporated, Minerva Neurosciences, OSI, Argan, and Approach Resources — New Research Emphasizes Economic Growth
NEW YORK, Feb. 05, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
- Simply Wall St.•6 months ago
How Much Of Minerva Neurosciences, Inc. (NASDAQ:NERV) Do Institutions Own?
Every investor in Minerva Neurosciences, Inc. (NASDAQ:NERV) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see Read More...
- GlobeNewswire•7 months ago
Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain
“In addition to providing further significant intellectual property protection for MIN-117, the pre-clinical data supporting the application suggest that this compound should be investigated beyond mood and anxiety disorders to include chronic pain, which is often a symptom of several neuro-psychiatric disorders,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. “Chronic pain is also one of the main reasons cited by patients with MDD who seek medical help,” said Dr. Luthringer.
- GlobeNewswire•7 months ago
Minerva Neurosciences to Present at Evercore ISI HealthCONx Conference on November 28, 2018
WALTHAM, Mass., Nov. 21, 2018 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to.
- GlobeNewswire•7 months ago
Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers
Findings suggest expanded therapeutic window and significantly improved cardiovascular safety margin compared to formulation used in Phase 2b trial All doses tested up to 256.
- Zacks•7 months ago
Minerva Neurosciences Sees Hammer Chart Pattern: Time to Buy?
Minerva Neurosciences has been struggling lately, but the selling pressure may be coming to an end soon.
- GlobeNewswire•7 months ago
Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 2018
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a roluperidone update and key opinion leader event on Tuesday, November 20, 2018 beginning at 8:00 a.m. Eastern Time in New York. Members of Minerva’s senior management will be joined by an expert key opinion leader.
- GlobeNewswire•7 months ago
New Research: Key Drivers of Growth for AxoGen, Spirit Realty Capital, e.l.f. Beauty, Minerva Neurosciences, Par Pacific, and Calithera Biosciences — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
